Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 148 of 6351
-
New drug combo shows promise in aggressive brain cancer trial
Disease control OngoingThe proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy …
Phase 2/3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Hope for rare heart disease: new drug aims to slow deadly protein clumps
Disease control OngoingThis study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
Phase 3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for hard-to-treat HIV: long-acting shot and pill combo tested
Disease control OngoingThe primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen for 14 days (functional monotherapy) in people with human immunodeficiency virus type 1 (HIV-1) (PWH) with multi-drug resista…
Phase 2/3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a single gene infusion rebuild failing hearts?
Disease control CompletedThis is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. 11 participants with non-ischemic cardiomyopath…
Phase 1 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New clotting factor shows promise in reducing bleeds for hemophilia a patients
Disease control CompletedPrimary Objective: \- To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episode…
Phase 3 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 18:07 UTC
-
Can a DNA-Based therapy revive Chemotherapy's power against resistant ovarian cancer?
Disease control CompletedPhase II, two arm prospective study of efficacy and safety of ELENAGEN in combination with gemcitabine in comparison with gemcitabine alone in patients with platinum-resistant ovarian cancer.
Phase 2 • Sponsor: CureLab Oncology • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene therapy offers new hope for sickle cell patients
Disease control CompletedThe purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the Sickle Cell disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the βAS3 globin g…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Dengue vaccine booster put to the test: can it shield against all four virus types?
Vaccine CompletedThe purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the f…
Phase 3 • Sponsor: Takeda • Aim: Vaccine
Last updated Aug 01, 2026 00:00 UTC
-
New CAR-T therapy aims to wipe out myeloma cells
Disease control OngoingThe purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a single pill replace the shot for gonorrhea?
Disease control CompletedThis trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azi…
Phase 3 • Sponsor: Global Antibiotics Research and Development Partnership • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo may keep lung cancer from returning after surgery
Disease control OngoingThe main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo aims to beat tough childhood leukemia
Disease control Recruiting nowThis phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare lung cancer mutation
Disease control OngoingCLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and …
Phase 1/2 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug aims to clear hidden leukemia before transplant
Disease control OngoingThis is a multi-center, phase 2A exploratory study of feasibility and effectiveness of Inotuzumab Ozagomicin in adult patients with Acute Lymphoid Leukemia (ALL) with positive minimal residual disease before any hematopoietic stem cell transplantation. The study is divided in tw…
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a biologic tame COPD's repeated Flare-Ups?
Disease control CompletedThis is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease (COPD) participants given as an add on to their optimi…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can an immune booster keep melanoma from returning after surgery?
Disease control OngoingThe purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a smart brain implant outsmart chronic pain?
Disease control Recruiting nowChronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in o…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A bold community experiment takes on the opioid crisis
Prevention CompletedThis study will test the impact of implementing the Communities That Helping to End Addiction Long-term (HEAL) intervention on opioid overdose deaths within 67 highly affected communities with the goal of reducing opioid overdose deaths by 40%.
Sponsor: RTI International • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy shows promise against tough uterine cancer
Disease control CompletedThe purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New daily injection could cut bleeding in Tough-to-Treat hemophilia
Disease control OngoingThis study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleed…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC